Expression systems for therapeutic glycoprotein production
Abstract
There are slightly over 165 recombinant pharmaceuticals currently approved for human use. Another 500 protein candidates are in preclinical and clinical development, about 70% of these being glycosylated proteins. The need for expression systems allowing the efficient manufacturing of high quality glycoproteins is thus becoming imperative. Recent developments with CHO cells, the predominant mammalian expression system, have focused on either increasing cell specific productivity or prolonging the life span of cells in culture that translates to high integrated viable cell densities. These two factors have allowed volumetric productivities in excess of 5 g/L under conditions of controlled nutrient feeding. In addition to glycoengineering strategies, which are offering considerable advantage in producing proteins with enhanced therapeutic properties, several alternative expression systems are being developed for their manufacture, each with their advantages and limitations.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Different gene amplification systems developed and used in CHO cells allow high titer yields and good specific productivity.
“Moreover, different gene amplification systems have been developed and used in CHO cells, which allow for high titer yields and good specific productivity (Durocher and Butler, 2009;Kim et al., 2012;Lai et al., 2013).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
Among mammalian-based expression systems, CHO cells are by far the most commonly used cell line.
“Among the mammalian-based expression systems, CHO cells is by far, the most commonly used cell line.”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
CHO cells are involved in the production of over 70% of recombinant biopharmaceutical proteins, most of them monoclonal antibodies.
“It is involved in the production of over 70% of recombinant biopharmaceutical proteins, most of them being monoclonal antibodies (mAbs) (Durocher and Butler, 2009;Kim et al., 2012;Butler and Spearman, 2014).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
Transgenic animals often produce different glycosylation patterns compared to native human proteins.
“As with other mammalian expression systems, transgenic animals often produce different glycosylation pattern compared to native human proteins (Durocher and Butler, 2009).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
Only two marketed recombinant glycoproteins are currently manufactured in BHK cells, Factor VIIa and Factor VIII.
“Only two marketed recombinant glycoproteins are currently manufactured in these cells, Factor VIIa (NovoSeven ® ) and Factor VIII (Kogenate ® and Kovaltry ® ), which are other clotting factors (Durocher and Butler, 2009;Dumont et al., 2015).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
BHK cells are mostly used for the production of vaccines.
“Baby Hamster Kidney (BHK) cells are mostly been used for the production of vaccines (Durocher and Butler, 2009).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
Successful apoptosis inhibition was also achieved by overexpression of other related anti-apoptotic proteins.
“Successful apoptosis inhibition was also achieved by overexpression of other related anti-apoptotic proteins (Durocher and Butler, 2009;Bandaranayake and Almo, 2014).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
Addition of sodium butyrate (NaB) and valproic acid (VPA) has resulted in increased productivity in numerous studies, especially in CHO cells.
“Addition of these chemicals has resulted in increased productivity in numerous studies, especially in CHO cells (Durocher and Butler, 2009;Yang et al., 2014).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
CHO Lec13 cells and rat hybridoma YB2/0 cells were employed, the former for its impaired synthesis of GDP-fucose and the latter for its reduced expression level of the fucosyltransferase FUT8.
“As early strategies, CHO Lec13 cells and rat hybridoma YB2/0 cells were employed, the former for its impaired synthesis of GDP-fucose and the latter for its reduced expression level of the fucosyltransferase FUT8 (Durocher and Butler, 2009).”
From Therapeutic glycoprotein production in mammalian cells (2017) · cites this paper as Durocher and Butler, 2009
Cites
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · see citing works
Davies, J., Jiang, L., Pan, L., LaBarre, M. J., Anderson, D., & Reff, M. (2001) · Biotechnology and Bioengineering · doi:10.1002/bit.1119 · Cited by 327 · see citing works
Jiang, Z., & Sharfstein, S. T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21726 · Cited by 118 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428 · see citing works
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372 · see citing works
Ghaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-28-147 · Cited by 320 · see citing works
Therapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296 · see citing works
Self-citationProduction of Highly Sialylated Monoclonal Antibodies
(2012) · InTech eBooks · doi:10.5772/51301 · Cited by 20 · see citing works
Self-citation
- Authors
- Durocher, Y., & Butler, M.
- Affiliations
- Biotechnology Research Institute (CA)
- University of Manitoba (CA)
- Corresponding author
- Durocher, Yves
- Butler, Michael
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 20
- Issue
- 6
- Pages
- 700-707
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W1994251377
- Cited by
- 386
- References
- 3
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 14 · 2023: 13 · 2022: 10 · 2021: 23 · 2020: 15 · 2019: 31 · 2018: 27 · 2017: 30 · 2016: 15 · 2015: 33 · 2014: 31 · 2013: 36 · 2012: 41
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- NPARC (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Viral Infectious Diseases and Gene Expression in Insects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Transgenic Plants and Applications
- Keywords
- recombinant protein expression systems, therapeutic glycoproteins, CHO cells, glycosylation, glycoengineering, cell-specific productivity, cell lifespan, nutrient feeding, volumetric productivity, biopharmaceutical manufacturing
- MeSH terms
- Animals, Biopharmaceutics, Cell Survival, Chemistry, Pharmaceutical, Cricetulus, Glycoproteins, Cricetinae, Humans, Insecta, Plants, Recombinant Proteins, Drug Design, Protein Engineering, CHO Cells, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review